Drug intelligence / Profile preview

CYP-004

Development stage: Unknown
Lead developer: Cynata Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

CYP-004 is an allogeneic mesenchymal stem cell (MSC) therapy developed by Cynata Therapeutics using its proprietary Cymerus™ platform. The Cymerus technology utilizes induced pluripotent stem cells (iPSCs) to produce a consistent and scalable supply of MSCs, bypassing the limitations of donor-derived MSCs. CYP-004 is currently being evaluated in the Phase III SCUlpTOR clinical trial, sponsored by the University of Sydney, for the treatment of knee osteoarthritis. The therapy aims to improve clinical outcomes and knee joint structure by leveraging the immunomodulatory and regenerative properties of MSCs.

Other names: Cymerus MSCCymerus mesenchymal stem cells

Beyond the preview

Go deeper on CYP-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYP-004.

Explore the full profile